Patricia Inácio, PhD,  science writer—

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) trial was assessing whether once-daily doses of bexotegrast (160 mg or 320 mg) could improve lung function in about 360 IPF patients, ages 40…

A Phase 1 clinical trial testing Cereno Scientific’s candidate therapy for idiopathic pulmonary fibrosis (IPF) in healthy volunteers has moved to its final part, the company has announced. This first-in-human, open-label trial is testing CS014 at single and multiple ascending doses in about 48 participants. The part that evaluated…

Low total cholesterol levels are linked to a higher risk of death among people with idiopathic pulmonary fibrosis, a new study from China with more than three years of follow-up data found. “We conducted a long-term follow-up study in patients with IPF and observed that lower [total cholesterol] levels…

Brainomix, a U.K.-based software company, has joined forces with Boehringer Ingelheim, a German pharmaceutical company, to accelerate the diagnosis of pulmonary fibrosis (PF) in the U.S. and improve treatment access for people with scarring of the lungs. As part of the collaboration, Brainomix’s artificial intelligence (AI)-powered tool, called Brainomix 360…

Acute exacerbations, or sudden bouts of symptom worsening, increase the mortality risk after lung transplantation in people with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), a study reports. While a lung transplant is considered an effective treatment for ILDs, these findings “suggest that caution is required during decision-making,…

A Phase 2a trial is recruiting people with idiopathic pulmonary fibrosis (IPF) to assess the effectiveness of GRI-0621, GRI Bio‘s investigational natural killer T-cell (NKT)-targeted therapy. The multicenter biomarker study, which was cleared to start by the U.S. Food and Drug Administration, is expected to have early results…

Bexotegrast, an oral anti-fibrotic treatment candidate from Pliant Therapeutics, is being assessed in a Phase 2b clinical trial in people with idiopathic pulmonary fibrosis (IPF). Called BEACON-IPF, it intends to recruit about 270 patients at clinical sites around the globe. Details on site locations and when recruitment will start…

Bridge Biotherapeutics has joined the Prognostic Lung Fibrosis Consortium, known as PROLIFIC — a global nonprofit working to speed the development of personalized treatment strategies for pulmonary fibrosis (PF), The long-term goal of PROLIFIC is to develop tests to detect biomarkers of distinct stages of the rare…

patientMpower and Qureight have joined forces to accelerate the discovery of new prognostic markers for interstitial lung diseases (ILDs), a group of lung diseases characterized by scarring and inflammation that includes idiopathic pulmonary fibrosis (IPF). The collaboration will harness Qureight’s artificial intelligence (AI) capability along with patientMpower’s…

Dosing is complete in the Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis at risk of developing pulmonary hypertension. In the blinded part of the study, which is now complete, participants were randomly assigned to receive nitric oxide or a placebo administered…